Morgan Stanley Maintains Overweight on Rhythm Pharmaceuticals, Lowers Price Target to $136

Benzinga Newsdesk www.benzinga.com Negative 84.4%

Neg 84.4% Neu 0% Pos 0%

Morgan Stanley analyst Jeffrey Hung maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and lowers the price target from $150 to $136.